# Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

> **NCT04337606** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Decitabine
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04337606
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-04
- **Primary completion:** 2024-04-04
- **Final completion:** 2026-04-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04337606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04337606, "Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04337606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*